ES2189956T3 - Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos. - Google Patents

Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.

Info

Publication number
ES2189956T3
ES2189956T3 ES97919665T ES97919665T ES2189956T3 ES 2189956 T3 ES2189956 T3 ES 2189956T3 ES 97919665 T ES97919665 T ES 97919665T ES 97919665 T ES97919665 T ES 97919665T ES 2189956 T3 ES2189956 T3 ES 2189956T3
Authority
ES
Spain
Prior art keywords
quinolina
medications
procedures
derivatives
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97919665T
Other languages
English (en)
Inventor
Teruo Oku
Hiroshi Kayakiri
Shigeki Satoh
Yoshito Abe
Yuki Sawada
Takayuki Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2189956T3 publication Critical patent/ES2189956T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE FORMULA (I) E LA QUE R 1 ES ALQUILO INFERIOR, R 2 ES UN GRUPO HETEROCICLICO, ETC., R 3 ES HIDROGENO, ALQUILO INFERIOR O HALOGENO, R 4 ES ALQUILO INFERIOR O HALOGENO, R 5 ES AMINO - SUSTITUIDO, CON SUSTITUYENTES SELECCIONADOS ENTRE EL GRUPO FORMADO POR EL ALQUILO INFERIOR Y EL ACILO, ETC., Y A ES ALQUILENO INFERIOR, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, ASI COMO A PROCESOS PARA SU PREPARACION, A UNA COMPOSICION FARMACEUTICA QUE LO INCLUYE, Y UN PROCEDIMIENTO PARA UTILIZARLO TERAPEUTICAMENTE EN LA PREVENCION Y/O TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA BRADIQUININA O SUS ANALOGOS EN SERES HUMANOS O ANIMALES.
ES97919665T 1996-04-29 1997-04-24 Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos. Expired - Lifetime ES2189956T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9526A AUPN952696A0 (en) 1996-04-29 1996-04-29 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2189956T3 true ES2189956T3 (es) 2003-07-16

Family

ID=3793840

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97919665T Expired - Lifetime ES2189956T3 (es) 1996-04-29 1997-04-24 Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.

Country Status (8)

Country Link
US (1) US6083959A (es)
EP (1) EP0900203B1 (es)
JP (1) JP2000509066A (es)
AT (1) ATE234818T1 (es)
AU (1) AUPN952696A0 (es)
DE (1) DE69719974T2 (es)
ES (1) ES2189956T3 (es)
WO (1) WO1997041104A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
EP1914236A1 (en) 2002-04-10 2008-04-23 Ortho-McNeil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
MA50804B1 (fr) 2017-11-24 2022-05-31 Pharvaris Netherlands B V Nouveaux antagonistes des récepteurs de bradykinine b2
AR118982A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
DK4203919T3 (da) 2021-08-05 2024-04-29 Pharvaris Gmbh Lipidbaseret sammensætning til oral administration af bradykinin-b2-receptorantagonister
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2023180575A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617183A1 (de) * 1985-11-16 1987-05-27 Bayer Ag Substituierte benzylether
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5212182A (en) * 1990-10-03 1993-05-18 American Home Products Corpooration Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
AU686115B2 (en) * 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
ATE269310T1 (de) * 1994-10-27 2004-07-15 Fujisawa Pharmaceutical Co Pyridopyrimidinone, chinoline und anellierte n- heterozyklen als bradykinin-antagonisten
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds

Also Published As

Publication number Publication date
JP2000509066A (ja) 2000-07-18
DE69719974D1 (de) 2003-04-24
EP0900203B1 (en) 2003-03-19
ATE234818T1 (de) 2003-04-15
AUPN952696A0 (en) 1996-05-23
EP0900203A1 (en) 1999-03-10
DE69719974T2 (de) 2003-08-28
US6083959A (en) 2000-07-04
WO1997041104A1 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
SV1998000029A (es) Compuestos de pirazina ref. pg3186
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
PA8442201A1 (es) Derivados de 6-fenilpiridil-2-amina
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ECSP014065A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
BR0312232A (pt) Inibidores de caspases e seus usos
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
BR9912581A (pt) Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica
PE20021016A1 (es) Conjugados de pregabalina-lactosa